CMPS Latest Headlines

COMPASS Pathways Reaffirmed at Buy as Analyst Highlights Late-Stage Data, Commercial Readiness and Keeps $23 Price Target Unchanged

at www.tipranks.com (Tue, 2-Jun 7:36 AM)

Compass Pathways Bolsters Governance as Kathleen Tregoning Joins Board Amid Key FDA Milestones

Market Chameleon (Thu, 28-May 8:40 AM)

Compass Pathways to Spotlight Psilocybin Innovation at Jefferies Global Healthcare Conference—What Should Investors Watch?

Market Chameleon (Tue, 26-May 7:54 AM)

COMPASS Pathways Sees Regulatory Momentum and Strong Financial Position as COMP360 Nears FDA Filing

Market Chameleon (Thu, 14-May 11:47 AM)

Compass Pathways Secures Accelerated FDA Review and Strengthens Cash Position Ahead of Blockbuster Launch for COMP360

Market Chameleon (Wed, 13-May 7:38 AM)

FDA Grants Compass Pathways Priority Voucher, Accelerating COMP360 Review for Treatment-Resistant Depression

Market Chameleon (Mon, 27-Apr 7:30 AM)

Compass Pathways Rises on White House Support and Strong Phase 3 Data for Psychedelic Treatment

Market Chameleon (Mon, 20-Apr 9:54 AM)

Compass Pathways Highlights Regulatory Progress with Needham Forum Appearance—What’s Next for Psychedelic Mental Health Treatment?

Market Chameleon (Mon, 20-Apr 7:05 AM)

Compass Pathways Launches U.S. Grant Program to Elevate Provider Training Ahead of Potential COMP360 Approval

Market Chameleon (Tue, 14-Apr 7:31 AM)

Compass Pathways Signals Confidence with Stifel CNS Forum Appearance as COMP360 Gains Regulatory Momentum

Market Chameleon (Thu, 12-Mar 9:01 AM)